Medscape: AFIRE encourages less antiplatelet use with novel oral anticoagulant for atrial fibrillation treatment
UC cardiologist weighs in on trial looking at therapies for heart patients
Medscape turned to the expertise of Richard Becker, MD, Director, UC Heart, Lung and Vascular Institute, when reporting the results of a randomized trial comparing an oral anticoagulation with an antiplatelet agent versus an oral anticoagulation alone in patients with both atrial fibrillation and stable coronary artery disease. Becker, also director of the UC Division of Cardiovascular Health and Disease in the College of Medicine and a UC Health cardiologist, authored a New England Journal of Medicine editorial on the results of the AFIRE trial.
Richard Becker, MD
Related Stories
Make Hoxworth Blood Center’s special holiday events part of your family celebrations this December
December 12, 2025
This December, Hoxworth Blood Center, University of Cincinnati, is inviting families across Greater Cincinnati to add something truly meaningful to their holiday traditions: giving the gift of life. With festive community events, beloved local partners and special thank-you gifts for donors, Hoxworth is making it easier, and more heartwarming than ever, to roll up your sleeves and help save lives close to home.
New combination treatment improves multiple myeloma outcomes
December 11, 2025
The University of Cincinnati Cancer Center's Ed Faber, DO, provided commentary to Medscape on the COBRA study that found the combination of carfilzomib combined with lenalidomide and dexamethasone (KRd) shows significantly greater efficacy than the previous standard of care.
Celebrating the newest Bearcats on Decision Day
December 11, 2025
The University of Cincinnati admits its newest Bearcats for Fall 2026. Interest in the university is at an all-time high with more than 35,000 applicants for admission. Decision Day was also a time to celebrate 10 new Marian Spencer Scholarship recipients.